Moderna annonce le succès d'un vaccin contre le cancer – et explose en bourse
L'action Moderna bondit de plus de 100% en pré-marché à New York après avoir annoncé le succès d'un essai d'un vaccin contre le mélanome, un cancer de la peau. Le géant pharmaceutique Merck, qui a…
Évaluation
Moderna's stock more than doubled in pre-market trading after reporting a successful trial for a skin cancer vaccine. The trial combined Moderna's mRNA technology with Merck's Keytruda and showed a significant improvement in preventing melanoma recurrence across over 1,100 patients. Merck shares also rose 8%. This positions mRNA technology beyond infectious disease applications, potentially opening a massive new market. Investors are betting this is not a one-off result but a platform breakthrough. The real test comes when full trial data is published and regulatory scrutiny begins.